Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Asma Beldi-Ferchiou

Showing results (21-30 of 24) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 24 results.
The Lancet. Haematology|September 24, 2020
Molecular response after obinutuzumab plus high-dose cytarabine induction for transplant-eligible patients with untreated mantle cell lymphoma (LyMa-101): a phase 2 trial of the LYSA groupSteven Le Gouill, Asma Beldi-Ferchiou, Marion Alcantara, et al.
Cell|February 11, 2021
Maturation and persistence of the anti-SARS-CoV-2 memory B cell responseAurélien Sokal, Pascal Chappert, Giovanna Barba-Spaeth, et al.
Blood Advances|January 26, 2021
Integrative analysis of a phase 2 trial combining lenalidomide with CHOP in angioimmunoblastic T-cell lymphomaFrançois Lemonnier, Violaine Safar, Asma Beldi-Ferchiou, et al.
Blood|November 28, 2019
Gene alterations in epigenetic modifiers and JAK-STAT signaling are frequent in breast implant-associated ALCLCamille Laurent, Alina Nicolae, Cécile Laurent, et al.
Pageof 3

Showing results (21-30 of 24) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 24 results.
The Lancet. Haematology|September 24, 2020
Molecular response after obinutuzumab plus high-dose cytarabine induction for transplant-eligible patients with untreated mantle cell lymphoma (LyMa-101): a phase 2 trial of the LYSA groupSteven Le Gouill, Asma Beldi-Ferchiou, Marion Alcantara, et al.
Cell|February 11, 2021
Maturation and persistence of the anti-SARS-CoV-2 memory B cell responseAurélien Sokal, Pascal Chappert, Giovanna Barba-Spaeth, et al.
Blood Advances|January 26, 2021
Integrative analysis of a phase 2 trial combining lenalidomide with CHOP in angioimmunoblastic T-cell lymphomaFrançois Lemonnier, Violaine Safar, Asma Beldi-Ferchiou, et al.
Blood|November 28, 2019
Gene alterations in epigenetic modifiers and JAK-STAT signaling are frequent in breast implant-associated ALCLCamille Laurent, Alina Nicolae, Cécile Laurent, et al.
Pageof 3